Abstract：
UNASSIGNED: To investigate the long-term efficacy and safety of adalimumab(ADA) in the treatment of patients with serpiginous choroiditis (SC) refractory to conventional therapy through quantitative parameters.
UNASSIGNED: A retrospective analysis was conducted on patients diagnosed with SC clinically and through fundus autofluorescence(FAF). Patients receiving ADA treatment were included. Demographic and clinical characteristics of the patients, association with tuberculosis (TB) infection, number of immunosuppressive therapies, recurrences, best corrected visual acuity (BCVA) change, and ADA-related side effects were recorded. The progression rate before and after ADA was calculated based on the area involved by FAF.
UNASSIGNED: Sixteen eyes of 8 patients (3 female/5 male) were enrolled to the study. The median (IQR) age was 53.5 (16.5) years. Diagnosis was SC in 4, ampiginous choroiditis in 3, and TB-related serpiginous-like choroiditis in 1 patient. Peripapillary involvement was present in 10 of 16 eyes. The area involved by FAF continued to progress under ADA treatment, however the progression rate was decreased (p = 0.143).The BCVA was preserved (p = 0.772). The number of systemic and local treatments decreased with ADA (p = 0.025 and 0.019, respectively). Additionally, the number of recurrences was reduced with ADA (p = 0.002). Median (IQR) follow-up was 45(28.75) months. Two patients experienced ADA-related side effects (pulmonary TBand rash).
UNASSIGNED: Our findings suggest a promising role for ADA in halting the progression of SC and have implications for improving outcomes. Despite the evidence in the literature at the level of case reports, ADA can be used effectively with close monitoring for potential risks.
UNASSIGNED: A retrospective analysis was conducted on patients diagnosed with SC clinically and through fundus autofluorescence(FAF). Patients receiving ADA treatment were included. Demographic and clinical characteristics of the patients, association with tuberculosis (TB) infection, number of immunosuppressive therapies, recurrences, best corrected visual acuity (BCVA) change, and ADA-related side effects were recorded. The progression rate before and after ADA was calculated based on the area involved by FAF.
UNASSIGNED: Sixteen eyes of 8 patients (3 female/5 male) were enrolled to the study. The median (IQR) age was 53.5 (16.5) years. Diagnosis was SC in 4, ampiginous choroiditis in 3, and TB-related serpiginous-like choroiditis in 1 patient. Peripapillary involvement was present in 10 of 16 eyes. The area involved by FAF continued to progress under ADA treatment, however the progression rate was decreased (p = 0.143).The BCVA was preserved (p = 0.772). The number of systemic and local treatments decreased with ADA (p = 0.025 and 0.019, respectively). Additionally, the number of recurrences was reduced with ADA (p = 0.002). Median (IQR) follow-up was 45(28.75) months. Two patients experienced ADA-related side effects (pulmonary TBand rash).
UNASSIGNED: Our findings suggest a promising role for ADA in halting the progression of SC and have implications for improving outcomes. Despite the evidence in the literature at the level of case reports, ADA can be used effectively with close monitoring for potential risks.
摘要：
■通过定量参数研究阿达木单抗（ADA）在治疗对常规治疗无效的血清色素脉络膜炎（SC）患者中的长期疗效和安全性。
■对临床和通过眼底自发荧光（FAF）诊断为SC的患者进行了回顾性分析。包括接受ADA治疗的患者。患者的人口统计学和临床特征，与结核病（TB）感染有关，免疫抑制疗法的数量，复发，最佳矫正视力（BCVA）变化，并记录ADA相关副作用。根据FAF涉及的面积计算ADA前后的进展率。
■8名患者(3名女性/5名男性)的16只眼被纳入研究。中位年龄（IQR）为53.5（16.5）岁。诊断为4例患者为SC，3例患者为氨状脉络膜炎，1例患者为TB相关的色素性脉络膜炎。16只眼中有10只存在乳头周围受累。FAF所涉及的领域在ADA治疗下继续取得进展，然而进展率下降(p=0.143).保留了BCVA(p=0.772)。ADA的全身和局部治疗的数量减少（分别为p=0.025和0.019）。此外,ADA组复发次数减少(p=0.002).中位随访时间（IQR）为45（28.75）个月。两名患者经历了ADA相关的副作用(肺TBand皮疹)。
■我们的研究结果表明，ADA在阻止SC进展方面具有很好的作用，并对改善预后具有意义。尽管文献中有病例报告层面的证据，ADA可以有效使用，并密切监测潜在风险。
■对临床和通过眼底自发荧光（FAF）诊断为SC的患者进行了回顾性分析。包括接受ADA治疗的患者。患者的人口统计学和临床特征，与结核病（TB）感染有关，免疫抑制疗法的数量，复发，最佳矫正视力（BCVA）变化，并记录ADA相关副作用。根据FAF涉及的面积计算ADA前后的进展率。
■8名患者(3名女性/5名男性)的16只眼被纳入研究。中位年龄（IQR）为53.5（16.5）岁。诊断为4例患者为SC，3例患者为氨状脉络膜炎，1例患者为TB相关的色素性脉络膜炎。16只眼中有10只存在乳头周围受累。FAF所涉及的领域在ADA治疗下继续取得进展，然而进展率下降(p=0.143).保留了BCVA(p=0.772)。ADA的全身和局部治疗的数量减少（分别为p=0.025和0.019）。此外,ADA组复发次数减少(p=0.002).中位随访时间（IQR）为45（28.75）个月。两名患者经历了ADA相关的副作用(肺TBand皮疹)。
■我们的研究结果表明，ADA在阻止SC进展方面具有很好的作用，并对改善预后具有意义。尽管文献中有病例报告层面的证据，ADA可以有效使用，并密切监测潜在风险。
